Palonosetron plus 3-day aprepitant and dexamethasone to prevent nausea and vomiting in patients receiving highly emetogenic chemotherapy
Flavia Longo(Policlinico Umberto I), Marisa Di Seri(Policlinico Umberto I), Silvia Quadrini(Policlinico Umberto I), Rita De Sanctis(Humanitas University), Amelia Altavilla(Policlinico Umberto I), Teresa Gamucci, I. D’Antoni(Policlinico Umberto I), Giovanni Mansueto(Ospedali Riuniti Umberto I), Ester Del Signore(Policlinico Umberto I), Cristina De Luca(Policlinico Umberto I), Vittoria Lapadula(Policlinico Umberto I), Bruno Gori(Policlinico Umberto I), Enrico Cortesi(Sapienza University of Rome), Luciano Stumbo(Ospedale San Filippo Neri), Roberta Grande, Barbara Cimadon(Policlinico Umberto I)
Cited by 38
Related Papers
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
|The Lancet Oncology|2012|5.5k
Initial Therapy with FOLFOXIRI and Bevacizumab for Metastatic Colorectal Cancer
|New England Journal of Medicine|2014|1.1k
Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial
|The Lancet Oncology|2017|493